Related by context. All words. (Click for frequent words.) 66 Bayer HealthCare Onyx Pharmaceuticals 65 VEGFR2 inhibitor 65 BRIM2 63 alvespimycin 63 opioid naive 63 5 fluorouracil leucovorin 63 IMPACT DCM 62 relapsed refractory AML 62 MKC# MT 62 sapacitabine CYC# 62 CTA# Injection 61 INSPIRE Trial Phase III 61 untreated de novo 61 humanized therapeutic 61 placebo controlled Phase 61 neovascular form 61 diagnosed Ph + 61 CG# oncolytic virus 61 evaluating picoplatin 61 unique alkylating agent 61 Randomized Phase II 61 albiglutide currently 61 relapsed MM 61 comparing alemtuzumab 61 metastatic castrate resistant 60 dependent kinase inhibitor 60 recurrent metastatic ovarian cancer 60 stage IIIb IV 60 LymphoStat B belimumab 60 multicenter dose escalation 60 evaluating mipomersen 60 pan histone deacetylase 60 recombinant PSMA vaccine 60 pralatrexate injection folate analogue 60 label multicenter randomized 60 antiretroviral naïve 60 ALN VSP Phase 60 multicenter Phase III 60 lintuzumab SGN 60 unresectable Stage III 60 label multicenter Phase 60 novel chimeric natriuretic 60 AVN# Phase 60 CYT# potent vascular disrupting 60 sorafenib Nexavar ® 59 counterfeiters clueless kinfolk 59 non myeloid malignancies 59 blinded randomized placebo controlled 59 Callisto initiated 59 metastatic CRPC 59 Annamycin 59 Ophena TM 59 EOquin TM phase 59 rALLy clinical trial 59 cutaneous T 59 Cloretazine R VNP#M 59 XL# SAR# 59 unresectable stage 59 papillary renal cell carcinoma 59 unresectable recurrent 59 albiglutide 59 HER2 positive metastatic breast 59 AKT inhibitor 59 Phase 1b 59 dose escalation trial 59 demonstrated antitumor activity 59 Sapacitabine 59 initiate multicenter 59 Randomized Phase 59 randomized controlled multicenter 59 refractory NSCLC 59 clinical trials Archexin 58 retinal vein occlusion induced 58 CEL SCI Phase III 58 kidney urologic 58 HCV NS5B polymerase 58 Ostabolin C TM 58 AVOREN 58 oral picoplatin 58 LHRH receptor positive 58 aflibercept VEGF Trap 58 metaglidasen 58 Initiated Phase 58 phase IIb study 58 metastatic androgen independent 58 phase Ib 58 subcutaneous PRO 58 multicenter randomized Phase 58 metastatic HRPC 58 Budesonide foam crofelemer 58 3 registrational trial 58 CML CP 58 TKB# 58 randomized controlled Phase 58 number NCT# ClinicalTrials.gov 58 cisplatin gemcitabine 58 BRIM3 58 multicenter randomized placebo controlled 58 comparing XIENCE V 58 multicenter Phase II 58 Luramist TM 58 multicenter Phase 58 Empatic ™ 58 treatment naive genotype 58 diagnosed glioblastoma 58 VICTOR E1 58 phase IIb clinical 58 diagnosed GBM 58 catheter occlusion 58 treatment naïve genotype 58 PI3K/Akt pathway inhibitor 58 sorafenib tablets 58 placebo controlled dose escalation 58 controlled multicenter 58 hypoxia activated prodrug 58 prednisone prednisolone plus 58 toenail onychomycosis 58 recurrent glioblastoma multiforme 58 leukemia AML 58 primary hypercholesterolemia 58 decompensated liver disease 58 eosinophilic asthma 58 sapacitabine 58 Cloretazine 58 forodesine 58 IMPACT DCM trial 58 ongoing Phase 1b 58 double blinded randomized 57 Phase 1b clinical trials 57 multicenter randomized controlled 57 registrational Phase 57 selective phosphodiesterase 57 Phase 2a clinical 57 Elotuzumab 57 testing huN# DM1 57 CATIE AD 57 dosing cohort 57 including eniluracil ADH 57 Phase 2a 57 leaky aortic valves 57 Qnexa TM 57 High Dose quadruples 57 imetelstat GRN#L 57 nilotinib Tasigna ® 57 galiximab 57 tramiprosate Alzhemed TM 57 refractory acute myeloid 57 lupus hepatitis C 57 NSABP C 57 docetaxel Taxotere R 57 metastatic castration resistant 57 systemic Phase 1b 57 dose escalation Phase 57 multicenter randomized 57 XL# anticancer compounds 57 Phase IIb randomized 57 brivanib 57 rash pruritus nausea 57 investigational monoclonal antibody 57 evaluating tivozanib 57 Heterozygous Familial Hypercholesterolemia 57 oral ghrelin agonist 57 Quinamed 57 bavituximab monotherapy trial 57 Phase Ib IIa 57 Testosterone MDTS R 57 MKC# MKC# PP 57 confirmatory pivotal 57 Syncria albiglutide 57 intravenous RSD# 57 CDAD Clostridium difficile 57 Matrix Phase 2b 57 Phase Ib II 57 PLX STROKE targeting 57 pharmacogenomic translational research 57 HGS ETR1 mapatumumab 57 worsening thrombocytopenia 57 prospective randomized multicenter 57 OAB overactive bladder 57 metastatic hormone refractory 57 ANCHOR trial 57 visilizumab 57 CRLX# 57 untreated AML 57 evaluating tesamorelin 57 ascending dose 57 evaluating T DM1 57 virus HCV protease inhibitor 57 MVA MUC1 IL2 57 recurrent NSCLC 56 PDX pralatrexate 56 MCSP respectively 56 8mg/kg 56 IMC #B 56 naïve HCV 56 memantine HCl 56 double blinded placebo 56 Phase 2a trial 56 Proellex TM 56 PROSTVAC VF 56 PORxin TM platforms 56 systemic juvenile idiopathic 56 Genasense R oblimersen 56 CR# vcMMAE 56 R ferumoxytol Injection 56 oral rivaroxaban 56 drug pipeline TAFA# 56 MAGE A3 ASCI 56 Study Evaluating 56 randomized multicenter 56 AIR CF1 56 de novo kidney transplant 56 class mGluR5 inhibitor 56 infliximab monotherapy 56 Crofelemer budesonide foam 56 Systemic Sclerosis 56 Testosterone MDTS ® 56 delta opioid receptor 56 novel VDA molecule 56 DEB# 56 Phase Ib 56 Elagolix 56 Placebo Controlled 56 immunotherapeutic agent 56 gastrin analogue TT 56 underwent liver transplantation 56 squamous histology 56 inhalations twice 56 dose dose escalation 56 multicenter placebo controlled 56 ATRA IV 56 generation purine nucleoside 56 bone marrow reticulin deposition 56 multicenter phase 56 Prodarsan R 56 refractory chronic lymphocytic 56 ORACLE MS 56 non nucleoside inhibitor 56 relapsed myeloma 56 SinuNase TM 56 severe hepatic insufficiency 56 oral ridaforolimus 56 fistulizing Crohn disease 56 TELINTRA R 56 IMA# 56 systemic lupus erythematosus rheumatoid 56 R sorafenib tablets 56 basal bolus regimen 56 OMP #R# 56 Completes Patient Enrollment 56 generation PNP inhibitor 56 rheumatoid arthritis inflammatory bowel 56 sequential dose escalation 56 relapsed refractory multiple myeloma 56 BR.# 56 FUSILEV enhances 56 pivotal Phase 56 stage IIIB IV 56 Tarvacin Anti Cancer 56 receptor tyrosine kinase inhibitor 56 aripiprazole Abilify 56 Mg Uk 56 multiple ascending dose 56 next generation URAT1 56 Telik logo TELINTRA 56 multicenter randomized double 56 dirucotide MBP# 56 evaluating Xcytrin 56 APEX PD 56 LymphoStat B TM 56 Pivotal Phase 56 non constipating irritable 56 weekly subcutaneous injections 56 prokinetic agent 56 chronic thromboembolic pulmonary 56 phase IIa 56 Folfox 56 Teriflunomide 56 RhuDex ™ 55 erlotinib Tarceva ® 55 R#/MEM # 55 Advaxis Phase 55 evaluating Prochymal 55 Second Pivotal Phase 55 humanized interleukin 6 55 anticancer compound 55 placebo controlled multicenter 55 Acute Myeloid Leukemia AML 55 mg administered orally 55 compound INCB# 55 Multicenter Randomized Double 55 GetGoal Phase III 55 TTR amyloidosis 55 deCODE AF TM 55 Initiates Phase II 55 autoantibody positive 55 hyperlipidemia hypertension 55 phase 2a 55 mGluR5 negative 55 cancer indications bafetinib 55 Rigel R# 55 telomerase inhibitor drug 55 RELOVAIR ™ 55 myocardial infarction ventricular fibrillation 55 Fovea Pharmaceuticals subsidiary 55 blinded placebo controlled 55 Tramiprosate ALZHEMED TM 55 randomized Phase 55 metastatic renal cell carcinoma 55 COU AA 55 acyclovir Lauriad R 55 randomized #:# 55 hyperlipidemic 55 recurrent metastatic 55 CIMZIA TM certolizumab pegol 55 PRECiSE 55 nonrandomized 55 Randomized Double blind 55 HCD# [002] 55 Pivotal Phase III 55 Oral NKTR 55 rALLy 55 pharmacologically active isomer 55 cetrorelix pamoate 55 castrate resistant prostate cancer 55 IPF CAPACITY 55 LUX Lung 55 Phase III Pivotal 55 evaluating satraplatin 55 OvaRex ® MAb 55 lenalidomide Revlimid R 55 R roscovitine 55 AML MDS 55 2 methoxyestradiol 55 Dr. Assa Amit 55 randomized #:#:# 55 zoledronic acid Reclast 55 Phase III randomized 55 diagnosed multiple myeloma 55 label dose escalation 55 FOLOTYN ® 55 Evoltra ® 55 TBC# 55 evaluating bavituximab 55 myelodysplastic myeloproliferative diseases 55 dasatinib Sprycel ® 55 dose escalation clinical 55 Randomized Double Blind 55 MKC# 55 RECORD1 55 initiate Phase IIa 55 COPEGUS ribavirin 55 stage IIIB 55 Pralatrexate 55 R roscovitine CDK cyclin 55 Stage IIIB IV 55 orally administered synthetic retinoid 55 chronic myeloid 55 KRAS mutations occur 55 IMiDs ® 55 RCW breast cancer 55 asymptomatic metastatic 55 Kinesin Spindle Protein KSP 55 mGluR5 NAM 55 Acute Exacerbations 55 Genasense ® oblimersen 55 Pruvel TM 55 OPT CHF 55 Phase IIIb 55 GVAX R 55 NS5B polymerase 55 clinical trials Archexin ® 55 diagnosed glioblastoma multiforme 55 Dementia Related Psychosis 55 TAXUS VI 55 RSD# oral 55 evaluating adecatumumab 55 Naive Patients 55 IMiDs R 55 AIR CF2 55 6 sulfatase 55 Phase 2b clinical 55 #/#/# Cytokinetics Incorporated 55 AAG geldanamycin analog 55 Hsp# Inhibitor 55 retaspimycin 55 azilsartan medoxomil 55 Phase III ADT 55 myelofibrosis polycythemia vera 55 dyskinesia PD LID 55 HIV HCV coinfected 55 FOLFOX6 chemotherapy regimen 55 MEND CABG 55 CINQUIL 55 LibiGel testosterone gel 55 controlled dose escalation 55 asthma rheumatoid arthritis 55 sunitinib malate 55 dose escalation phase 55 Dapagliflozin 55 sarcoma melanoma 54 Curis collaborator Genentech 54 Albuferon TM 54 docetaxel chemotherapy 54 refractory gout 54 Capesaris 54 lead Aganocide compound 54 dose intramuscular 54 recurrent malignant glioma 54 hepatorenal syndrome 54 malignant mesothelioma Alfacell 54 bazedoxifene conjugated estrogens 54 Dacogen injection 54 Phase IIb trials 54 either acutely decompensated 54 psoriatic arthritis PsA 54 Ribavirin causes 54 REVIVE Diabetes 54 exploratory Phase IIa 54 catheter occlusion CO 54 FOLFIRI alone 54 onset idiopathic hypogonadism 54 Phase Ia 54 seliciclib CYC# 54 non metastatic osteosarcoma 54 Initiate Phase 54 Khodorkovsky exchanged glances 54 reduce serum phosphate 54 CTAP# Capsules 54 IL# PE#QQR 54 Curaxin CBLC# 54 biliary tract cancer 54 alfimeprase direct 54 Enzastaurin 54 label multicenter 54 INCB# [001] 54 iloprost synthetic compound 54 generation DACH Platinum 54 Combination REOLYSIN R 54 PROVENGE ® 54 CYP#A# CYP#D# 54 metastatic dermatofibrosarcoma protuberans DFSP 54 generation Hsp# inhibitor 54 relapsed ALL 54 randomized Phase III 54 metastatic bladder 54 Phase #b/#a clinical 54 VESTASYNC II trial 54 monoclonal antibody IgG1 Mab 54 Neovascular AMD 54 hGH CTP Phase 54 mixed hyperlipidemia 54 IIa trial 54 relapsed leukemia 54 estramustine 54 Cannabinor 54 phase III isavuconazole 54 evaluate ZFP Therapeutic 54 Sanofi Pasteur Fluzone 54 Alocrest 54 trial evaluating PRX# 54 oral Janus kinase 54 metastatic gastric 54 cediranib 54 castration resistant prostate cancer 54 huC# DM4 54 ocular formulation 54 Aflibercept 54 REGN# 54 ACTEMRA TM 54 acute peripheral arterial 54 Mg Usa 54 Panzem R 54 development peramivir neuraminidase 54 sodium thiosulfate STS 54 HCV SPRINT 54 orally administered inhibitor 54 Researchers randomly assigned 54 avosentan 54 HGS ETR1 54 oral JAK#/JAK# inhibitor 54 blind multicenter 54 LX# LX# 54 Phase IIa trial 54 GATTEX ™ 54 Epothilone D 54 receiving XGEVA 54 combines Zetia 54 TRIOLEX HE# APOPTONE HE# 54 avanafil PDE5 inhibitor 54 diagnosed Glioblastoma multiforme 54 GALNS 54 occlusion PAO 54 Recurrent Glioblastoma 54 orally inhaled migraine 54 Phase #b/#a trial 54 ChronVac C R 54 TMC# [002] 54 PEGylated docetaxel 54 ospemifene 54 ascending dose study 54 Phase 2a clinical trials 54 HGS ETR2 54 octreotide implant 54 Edge STudy 54 irinotecan doxorubicin oxaliplatin paclitaxel 54 ADVANCE PD 54 Placebo controlled 54 oral deforolimus 54 candidate CRLX# 54 dacarbazine DTIC 54 Phase III multicenter 54 intravesical infusion therapy 54 Tarceva TM 54 custirsen 54 GEM OS2 54 rheumatoid arthritis psoriatic arthritis 54 neuropathic pain spasticity 54 RAS MAPK pathway 54 Pharmacokinetics PK 54 multicenter multinational 54 telomerase therapeutic 54 fosbretabulin 54 adecatumumab MT# 54 CHAMPION PCI 54 refractory metastatic colorectal cancer 54 TTF Therapy 54 clinical trials SGN 54 DepoCyt ® Abelcet ® 54 ovarian endometrial 54 overactive bladder AA# 54 Phase 2b Clinical Trial 54 immunocompetent adults 54 INS# [001] 54 Atiprimod 54 Panzem R NCD 54 phase IIb 54 Genz # 53 blind placebo 53 refractory multiple myeloma 53 tolevamer 53 PEG SN# 53 chemotherapy FOLFOX 53 nonsmall cell lung cancer 53 Hodgkin lymphoma HL 53 atrial fibrillation budiodarone ATI 53 Ozarelix 53 randomized placebo controlled 53 antiretroviral naive 53 Phase Ib clinical 53 Omacetaxine 53 Phase III placebo controlled 53 obesity dyslipidemia 53 phase IIa clinical 53 sodium Injection 53 elacytarabine 53 refractory metastatic 53 administered subcutaneously 53 metastatic malignant melanoma 53 riociguat 53 randomized discontinuation trial 53 ZYBRESTAT fosbretabulin 53 randomized multicentre 53 MEND CABG II 53 sodium glucose cotransporter 53 subcutaneous formulation 53 Locteron ® 53 deforolimus 53 IMC A# 53 sorafenib Nexavar 53 refractory chronic myeloid 53 dacarbazine chemotherapy 53 nab paclitaxel 53 QNEXA ® 53 evaluating Actimmune 53 dose escalation study 53 low dose cytarabine 53 interferon gamma 1b 53 dose escalation 53 Trial Evaluating 53 ® bortezomib 53 PPI omeprazole 53 prospective multicenter randomized 53 unstable angina UA 53 Phase #/#a trial 53 regorafenib 53 adalimumab Humira 53 Anturol TM 53 undergoing elective percutaneous 53 GAMMAGARD 53 R rilonacept Injection 53 advanced metastatic prostate 53 ascending doses 53 Aplidin R 53 plus gemcitabine 53 By JENNIFER LEARN 53 paclitaxel Taxol ® 53 FLT3 mutations 53 histologically confirmed 53 cutaneous T cell 53 dacetuzumab SGN 53 ZOLINZA 53 Amrubicin 53 Fx #A 53 metastatic renal cell 53 relapsing remitting MS RRMS 53 Bezielle 53 NOX E# 53 Dose Escalation 53 atherosclerosis rheumatoid arthritis 53 childbearing age mirrors 53 antidepressants fluoxetine 53 K ras mutations 53 Zemplar Capsules 53 dose pharmacokinetic 53 Denufosol 53 Depressed bipolar 53 oral chemotherapeutic agent 53 homozygous familial hypercholesterolemia 53 trivalent inactivated influenza 53 dosing cohorts 53 CCR5 mAb 53 pelvic malignancies 53 randomized Phase IIb 53 sulfonylurea glimepiride 53 landmark ATHENA 53 integrin inhibitor 53 assessing T DM1 53 Canvaxin TM 53 brand ciclesonide HFA 53 treat secondary hyperparathyroidism 53 alfa 2a 53 Phase 2b study 53 Phase IIa trials 53 acute myelogenous leukemia AML 53 Phase IIb 53 Related Disorders Support 53 mertansine 53 Myelodysplastic syndromes 53 solid tumors ZYBRESTAT 53 HBeAg negative 53 ABSSSI 53 opioid induced bowel dysfunction 53 underwent resection 53 DDP# 53 Exherin TM 53 EmbraceAC 53 nonmetastatic 53 Copegus ® ribavirin 53 BAY #-# 53 TASKi2 53 MEK Inhibitor 53 Metastatic Melanoma 53 Romidepsin 53 recurrent glioblastoma 53 metastatic renal 53 herpetic keratitis 53 mg/m2 dose 53 PD LID 53 Seliciclib 53 Alzheimer disease cognitive impairment 53 underwent surgical resection 53 blinded randomized 53 BrachySil TM 53 MIVI III 53 Achieves Primary Endpoint 53 bile duct tumor 53 evaluating carfilzomib 53 EMPOWER ™ 53 multicentre randomized 53 HCV RESPOND 2 53 idiopathic thrombocytopenic purpura 53 CLARITY study 53 NATRECOR ® 53 null responder HCV 53 Brentuximab Vedotin SGN 53 tolerability pharmacokinetics 53 ZACTIMA 53 RESTORE CLI trial 53 maximally tolerated dose 53 Temsirolimus 53 previously untreated follicular 53 tosedostat 53 placebo controlled clinical 53 investigational protease inhibitor 53 multicentre randomized double 53 midstage clinical 53 metastatic malignant 53 SUCCEED trial 53 liposomal formulation 53 Actonel risedronate 53 CAMMS# 53 brain metastases originating 53 baminercept 53 phase IIIb 53 undergone radical prostatectomy 53 Afatinib 53 heavily pretreated 53 Philadelphia Chromosome Positive 53 patientswith 53 REG2 53 randomized Phase 2b 53 GATTEX ® 53 fallopian tube cancers 52 observer blinded randomized 52 Dosa suffers 52 Tyrima 52 cell lymphoma CTCL 52 Ph + acute lymphoblastic 52 lymphoma CTCL 52 Oral Fingolimod 52 telaprevir dosed 52 lymphoid malignancies 52 placebo controlled randomized 52 pharmacokinetic PK study 52 relapsed multiple myeloma 52 anemia COPD 52 ELACYT 52 anthracycline taxane 52 multinational multicenter randomized 52 Obatoclax 52 PANVAC VF 52 severe oral mucositis 52 melphalan prednisone 52 investigational compounds 52 ergot derivatives 52 NO# [002] 52 antibody MAb 52 Aztreonam lysine 52 Clolar ® 52 dasatinib Sprycel 52 advanced carcinoid 52 platinum refractory 52 Archexin 52 interferon alfa 2a 52 Chaman Ara 52 Multiple Ascending Dose 52 ThermoDox R 52 Phase IIa 52 budesonide foam 52 5 FU capecitabine 52 Altera Nebulizer System 52 Genasense oblimersen sodium Injection 52 ziprasidone Geodon 52 EVIZON TM squalamine lactate 52 paclitaxel poliglumex 52 randomized 52 Prostate AdenoCarcinoma Treatment 52 NOXAFIL Oral Suspension 52 progressive metastatic prostate 52 Selzentry Celsentri 52 serologically active systemic lupus 52 pegylated interferon alpha 52 small molecule chemotherapeutic 52 oral prodrug 52 Phase 2b randomized 52 dyslipidemia hypertension diabetes 52 ACCORD COPD 52 PARTNER Trial 52 DU #b 52 Phase III randomized controlled 52 intradermal injections 52 prospectively stratified 52 dose cohort 52 including cyclosporine methotrexate 52 immuno compromised individuals 52 fostamatinib 52 initiate Phase 1b 52 neratinib 52 bepotastine besilate nasal spray 52 IIa clinical 52 metastatic adenocarcinoma 52 Pimavanserin 52 candidate AQ4N 52 Traficet EN 52 Genasense ® 52 PRECISE Trial 52 EXPLORE Xa 52 Amgen Neulasta ® 52 Sprycel dasatinib 52 PrevOnco ™ 52 lorcaserin Phase 52 symptomatic BPH 52 Safinamide 52 elotuzumab 52 Personalized Immunotherapy 52 Daclizumab 52 Phase IIb clinical 52 TLK# 52 demonstrated clinically meaningful 52 clinical trials dacetuzumab SGN 52 Trastuzumab DM1 52 Phase 2b clinical trials 52 trastuzumab DM1 T DM1 52 plus prednisone prednisolone 52 PREZISTA r 52 atypical hemolytic uremic syndrome 52 mg Pycnogenol 52 PRIMO CABG 52 oropharyngeal candidiasis OPC 52 KRN# 52 Phase Ib clinical trials 52 subcutaneous SC 52 mCRC patients 52 Phase 2b 52 dose cohorts 52 Albuferon Phase 52 Aryplase 52 venlafaxine XR 52 Phase IIa clinical 52 Panzem NCD 52 ganetespib 52 peripherally acting 52 multidose 52 IVs crying 52 cetuximab Erbitux R 52 COR Diabetes 52 investigational oral 52 Successfully Completes Phase 52 BENICAR HCT 52 comparator arm 52 pazopanib 52 vaccinated PNH patients 52 PEGINTRON REBETOL combination 52 chlorambucil 52 cisplatin chemotherapy 52 Phase lll 52 Waldenstrom macroglobulinemia 52 granted Ortec 52 coronary stent merged 52 Zemiva ™ 52 Novolimus 52 EDEMA3 52 access graft VAG 52 torezolid phosphate 52 oxypurinol 52 Syncria ® 52 pegylated interferon alfa 2a 52 Omnitarg 52 Vicinium TM 52 #mg ATC 52 BLOOM Behavioral modification 52 mg q#h 52 lintuzumab 52 acute myeloid 52 Kit CD# positive 52 discontinued Viread 52 LEP ETU 52 developing Bicifadine serotonin 52 PEGylated interferon 52 Pre RELAX AHF 52 volociximab 52 clinical trials Multikine 52 PTH analogue 52 Phase 2b Trial 52 CEQ# 52 pharmacokinetics PK 52 aspirin clopidogrel 52 Initiates Enrollment 52 masked placebo controlled 52 Carotid Revascularization Endarterectomy vs. 52 severe hypercholesterolemia 52 Meets Primary Endpoint 52 #mg QD [002] 52 FREE HEARING SCREENING 52 Onrigin 52 Eniluracil 52 Wisconsin Sleep Cohort 52 patients undergoing percutaneous 52 cancer neuroendocrine tumor 52 initiated Phase Ib 52 metformin sulfonylureas 52 PEG PAL 52 PMX # heptagonist 52 sunitinib Sutent ® 52 randomized crossover 52 trastuzumab Herceptin R 52 II Clinical Trial 52 Completes Enrollment 52 sorafenib Nexavar R 52 Prospective Randomized 52 progressive PsA 52 IIb clinical trial 52 single ascending dose 52 known dihydropyrimidine dehydrogenase 52 ritonavir boosted protease inhibitor 52 dexpramipexole 52 pharmacokinetics pharmacodynamics 52 systemic ALCL 52 systemically administered 52 placebo controlled Phase III 52 Pharmos pipeline 52 acarbose 52 4mg/kg 52 Vidaza ® 52 IV NSCLC 52 diarrhea predominant irritable 52 Hedgehog Pathway Inhibitor 52 prospective randomized placebo 52 achieved ACR# 52 PRIMO CABG2 52 ACAPODENE 52 PEGINTRON TM 52 underwent CABG 52 potent triglyceride lowering 52 trastuzumab emtansine T DM1 52 lesinurad 52 DG# compounds targeting 52 Xeloda ® 52 Allovectin 7 ® 52 Stage IIIb IV 52 PRT# 52 Sudhir Agrawal D.Phil 52 receiving VELCADE 52 docetaxel prednisone 52 cisplatin vinorelbine 52 generation proteasome inhibitor 52 REVIVE TA 52 PHX# 52 dextromethorphan quinidine 52 Pegasys plus Copegus 52 related DHFR inhibitors 52 Acetavance TM intravenous acetaminophen 52 desvenlafaxine succinate 52 metformin sulfonylurea 52 Tanespimycin 51 Phase 1a clinical 51 anastrazole 51 multi kinase inhibitor 51 Vicriviroc 51 certolizumab 51 teriflunomide 51 CHOP chemotherapy 51 Syncria R 51 CFTR corrector 51 dexamethasone Decadron 51 pontiff forgave 51 cytarabine daunorubicin 51 thalidomide Thalomid 51 headache nasopharyngitis 51 osteoporotic vertebral compression fractures 51 Phenoptin 51 vidofludimus 51 #:# randomization 51 Forodesine 51 Aplidin 51 allosteric modulator NAM 51 Myelodysplastic syndromes MDS 51 PRX # 51 Phase 1b clinical 51 XL# XL# XL# 51 RGB # 51 receiving INTRON 51 IMPACT IMmunotherapy 51 painful diabetic neuropathy 51 evaluating bafetinib 51 palifosfamide Zymafos TM 51 Phase #b/#a 51 nucleotide analogue 51 alemtuzumab Campath 51 OMP #M# 51 Phase IIa Clinical Trial 51 ARRY # 51 designated HVTN 51 novel histone deacetylase 51 retinal thrombosis hemorrhages 51 Phase IIIb clinical 51 Methylnaltrexone 51 refractory cutaneous T 51 HGS# 51 familial amyloidotic polyneuropathy FAP 51 HepeX B TM 51 fallopian tube carcinoma 51 GRNVAC1 51 active comparator 51 hypereosinophilic syndrome 51 TAXUS IV 51 IIa clinical trials 51 VA# [002] 51 sargramostim 51 EQUIP OB 51 PNP inhibitor 51 crizotinib PF # 51 risperidone Risperdal 51 NPH insulin 51 e Forcibly transferring 51 Prostate Lung Colorectal 51 Phase Ib study 51 CAPACITY trials 51 PEGylated irinotecan 51 relapsing multiple sclerosis 51 HIV coinfected 51 Clinical Antipsychotic Trials 51 tumors GIST 51 TO AVOID PREGNANCY WHILE 51 convulsive disorders 51 registrational trial 51 Glufosfamide 51 dose titration